<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03844217</url>
  </required_header>
  <id_info>
    <org_study_id>2018-02205; me18ChristCrain4</org_study_id>
    <nct_id>NCT03844217</nct_id>
  </id_info>
  <brief_title>Copeptin After an Oral Stimulation With Macimorelin in Healthy Volunteers</brief_title>
  <acronym>Macicop</acronym>
  <official_title>Copeptin After an Oral Stimulation With Macimorelin in Healthy Volunteers - The Macicop-Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates stimulation of the posterior pituitary gland by oral Macimorelin (a
      ghrelin receptor Agonist) to be a novel diagnostic test in the polyuria-polydipsia syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Copeptin measurements upon intravenous arginine stimulation discriminate patients with
      diabetes insipidus versus patients with primary polydipsia with a high diagnostic accuracy.
      An oral test would be easier to perform, causes less risks and discomfort for the patients
      and would require less resources in clinical practice. This study investigates stimulation of
      the posterior pituitary gland by oral Macimorelin (a ghrelin receptor Agonist) to be a novel
      diagnostic test in the polyuria-polydipsia syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 7, 2019</start_date>
  <completion_date type="Actual">July 16, 2019</completion_date>
  <primary_completion_date type="Actual">July 16, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Prospective, proof-of concept diagnostic study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Copeptin value (pmol/l), after intake of Macimorelin of 0.5mg/kg body weight</measure>
    <time_frame>baseline blood exam (timepoint 0) and further blood collections after 30, 45, 60, 90 and 120 minutes after baseline blood collection</time_frame>
    <description>evaluate copeptin values after the intake of of a single oral-dose Macimorelin of 0.5mg/kg body weight</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Copeptin value (pmol/l), after intake of Macimorelin of 0.75mg/kg body weight</measure>
    <time_frame>baseline blood exam (timepoint 0) and further blood collections after 30, 45, 60, 90 and 120 minutes after baseline blood collection</time_frame>
    <description>evaluate copeptin values after the intake of of a single oral-dose Macimorelin of 0.75mg/kg body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Growth Hormone (GH) value (ng/mL)</measure>
    <time_frame>baseline blood exam (timepoint 0) and further blood collections after 30, 45, 60, 90 and 120 minutes after baseline blood collection</time_frame>
    <description>evaluate GH values after the intake of of a single oral-dose Macimorelin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin-like growth factor 1 (IGF-1) value (yg/mL)</measure>
    <time_frame>baseline blood exam (timepoint 0) and further blood collections after 30, 45, 60, 90 and 120 minutes after baseline blood collection</time_frame>
    <description>evaluate IGF-1 values after the intake of of a single oral-dose Macimorelin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in free thyroxine (fT4) value (ng/dL)</measure>
    <time_frame>baseline blood exam (timepoint 0) and further blood collections after 30, 45, 60, 90 and 120 minutes after baseline blood collection</time_frame>
    <description>evaluate fT4 values after the intake of of a single oral-dose Macimorelin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Thyreotropin (TSH) value (mU/L)</measure>
    <time_frame>baseline blood exam (timepoint 0) and further blood collections after 30, 45, 60, 90 and 120 minutes after baseline blood collection</time_frame>
    <description>evaluate TSH values after the intake of of a single oral-dose Macimorelin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Prolactin value (yg/L)</measure>
    <time_frame>baseline blood exam (timepoint 0) and further blood collections after 30, 45, 60, 90 and 120 minutes after baseline blood collection</time_frame>
    <description>evaluate Prolactin values after the intake of of a single oral-dose Macimorelin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cortisol value (ng/mL)</measure>
    <time_frame>baseline blood exam (timepoint 0) and further blood collections after 30, 45, 60, 90 and 120 minutes after baseline blood collection</time_frame>
    <description>evaluate Cortisol values after the intake of of a single oral-dose Macimorelin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Adrenocorticotropin (ACTH) value ( pg/mL)</measure>
    <time_frame>baseline blood exam (timepoint 0) and further blood collections after 30, 45, 60, 90 and 120 minutes after baseline blood collection</time_frame>
    <description>evaluate ACTH values after the intake of of a single oral-dose Macimorelin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Luteotropin (LH) value (U/L)</measure>
    <time_frame>baseline blood exam (timepoint 0) and further blood collections after 30, 45, 60, 90 and 120 minutes after baseline blood collection</time_frame>
    <description>evaluate LH values after the intake of of a single oral-dose Macimorelin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Follicle-stimulating hormone value(FSH) (IU/mL)</measure>
    <time_frame>baseline blood exam (timepoint 0) and further blood collections after 30, 45, 60, 90 and 120 minutes after baseline blood collection</time_frame>
    <description>evaluate FSH values after the intake of of a single oral-dose Macimorelin</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Polyuria-polydipsia Syndrome</condition>
  <arm_group>
    <arm_group_label>Macimorelin 0.5mg/kg body weight</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Visit 1: oral Macimorelin stimulation test with the dose of 0.5mg/kg body weight Macimorelin.
Visit 2: After a washout-phase of 1 week, participants will undergo the oral Macimorelin stimulation test with the dose of 0.75mg/kg body weight. Study procedures are equal compared to visit 1.
Macimorelin 0.75mg/kg body weight</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Macimorelin 0.5mg/kg body weight</intervention_name>
    <description>oral Macimorelin stimulation test with the dose of 0.5mg/kg body weight Macimorelin</description>
    <arm_group_label>Macimorelin 0.5mg/kg body weight</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Macimorelin 0.75mg/kg body weight</intervention_name>
    <description>oral Macimorelin stimulation test with the dose of 0.75mg/kg body weight Macimorelin</description>
    <arm_group_label>Macimorelin 0.5mg/kg body weight</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No medication except hormonal contraception

        Exclusion Criteria:

          -  Body Mass Index (BMI) &gt; 40kg/m2 or BMI &lt; 18.5 kg/m2

          -  participation in a trial with investigational drugs within 30 days

          -  vigorous physical exercise within 24 hours before the study participation

          -  Alcohol intake within 24 hours before study participation

          -  pregnancy and breastfeeding

          -  Evidence of disordered drinking habits and diuresis defined as polyuria &gt;50ml/kg body
             weight/24h and polydipsia &gt;3l /24h

          -  a prolonged QT interval (QTc &gt;500 ms) or concomitant treatment with drugs that prolong
             the QT/QTc.

          -  Intention to become pregnant during the course of the study

          -  Known allergy towards Macimorelin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mirjam Christ-Crain, Prof. Dr. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endocrinology, Diabetes and Metabolism, University Hospital Basel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Basel Endocrinology, Diabetes and Metabolism</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>February 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2019</study_first_posted>
  <last_update_submitted>August 7, 2019</last_update_submitted>
  <last_update_submitted_qc>August 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Copeptin</keyword>
  <keyword>Macimorelin</keyword>
  <keyword>Ghrelin receptor agonist</keyword>
  <keyword>posterior pituitary gland</keyword>
  <keyword>polyuria-polydipsia syndrome</keyword>
  <keyword>hypothalamo-pituitary-adrenal axis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Insipidus</mesh_term>
    <mesh_term>Polyuria</mesh_term>
    <mesh_term>Polydipsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tryptophan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

